Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Non-Current Assets (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Non-Current Assets for 8 consecutive years, with $35.7 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 13.82% to $35.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $158.5 million through Dec 2025, up 22.07% year-over-year, with the annual reading at $35.7 million for FY2025, 13.82% down from the prior year.
  • Non-Current Assets for Q4 2025 was $35.7 million at Precision Biosciences, down from $41.8 million in the prior quarter.
  • The five-year high for Non-Current Assets was $49.7 million in Q4 2021, with the low at $18.5 million in Q3 2023.
  • Average Non-Current Assets over 5 years is $38.0 million, with a median of $41.6 million recorded in 2024.
  • The sharpest move saw Non-Current Assets tumbled 60.12% in 2023, then soared 131.1% in 2024.
  • Over 5 years, Non-Current Assets stood at $49.7 million in 2021, then fell by 21.47% to $39.1 million in 2022, then crashed by 40.04% to $23.4 million in 2023, then skyrocketed by 76.75% to $41.4 million in 2024, then decreased by 13.82% to $35.7 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $35.7 million, $41.8 million, and $38.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.